Widely used metabolic drugs may help curb rising colorectal cancer in younger adults

March 2, 2026

A large, retrospective study conducted by scientists at The University of Texas at San Antonio suggests that people taking glucagon-like peptide-1 (GLP-1) receptor agonists — medications that are widely prescribed for metabolic disease — have a significantly lower risk of developing colorectal cancer compared with those taking aspirin.



Robotic surgery on forefront of HPV-related cancer treatment

February 3, 2026

This story was first published in the February 2026 issue of the Bexar County Medical Society’s San Antonio Medicine magazine. New face of head and neck cancer A healthy 40-year-old man visits his primary care physician for a mass on his neck. He doesn’t smoke, has no risk factors for head and neck cancer, and […]